Reprogramming Transplant Immunity: A New Frontier in Gene Therapy
In this session, Frank brings decades of leadership in biotechnology and gene therapy to explore a transformative approach to transplant medicine. Drawing on his experience across biopharma, diagnostics, and immunotherapy, he will share how Allogenetics is pioneering a novel strategy to improve transplant outcomes through ex vivo gene therapy.
Why Frank’s Session Matters
Organ transplantation saves lives, but lifelong immunosuppression remains a major burden, exposing patients to serious side effects and limiting long-term success. This session highlights a breakthrough approach that aims to eliminate that trade-off by enabling immune tolerance without compromising protection. By fine-tuning antigen presentation in donor organs, Allogenetics is working toward one-time treatments that could dramatically improve graft survival, patient quality of life, and ultimately help address the global organ shortage.
About Frank Schnieders
Frank is an experienced biotechnology executive and serial entrepreneur with decades in viral gene therapy, cancer immunotherapy, molecular diagnostics, and gene therapy for transplant engineering. He gained his biopharma experience as CEO at Provecs Medical, at Evotec and as CEO of LAMPseq Diagnostics in Bonn, Germany. Frank joined Allogenetics in 2024 and took over the role as CDO and managing director in 2025. He has a proven track record in founding and financing of biotech companies. Frank is a biochemist holding a PhD in human genetics from Hannover Medical School (MHH), with following scientific positions at Max-Delbrück-Center for Molecular Medicine in Berlin, at the Heinrich-Pette-Institute for Immunology and Experimental Virology and at UKE Hamburg. He is the author of numerous scientific publications and the inventor of several gene therapy vector patent families. As an active member of several biotechnology associations, he is part of a large international network of leading representatives from industry and science.
About Allogenetics
Allogenetics’ mission is to enable longer and healthier lives for transplant patients by fine-tuning the balance between immune tolerance and protection. We are advancing an ex vivo gene therapy designed as a one-time treatmentto modify the donor organ. Our goal is to eliminate the need for lifelong immunosuppression and its challenges to improve graft survival and patient quality of life. The company’s proprietary technology platform enables a calibrated knockdown of cell-surface antigen presentation (MHC class I and II) to evade graft rejection while retaining full immune competence. Building on compelling proof-of-concept in animal models, we will bring our novel organ-agnostic approach into human clinical trials, starting with lung and kidney grafts. By leveraging our immune-tolerance approach we are building a new path toward addressing life-threatening conditions and the global organ shortage crisis. Allogenetics is a spin-out from Hannover Medical School, Hannover, Germany.
Allogenetcs
2001
Hannover, Germany
Ex-vivo gene therapy to prevent rejection
